Insmed (NASDAQ:INSM) Director Sells $3,100,000.00 in Stock

Insmed, Inc. (NASDAQ:INSM) Director David Brennan sold 25,000 shares of the company’s stock in a transaction dated Wednesday, September 9th. The shares were sold at an average price of $124.00, for a total transaction of $3,100,000.00. Following the completion of the transaction, the director directly owned 39,238 shares of the company’s stock, valued at approximately $4,865,512. The trade was a 38.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Insmed Stock Up 1.7%

Shares of NASDAQ INSM traded up $2.18 during midday trading on Friday, reaching $129.46. 1,698,200 shares of the company’s stock were exchanged, compared to its average volume of 2,960,716. Insmed, Inc. has a 52-week low of $90.39 and a 52-week high of $212.75. The stock has a market capitalization of $28.27 billion, a PE ratio of -31.50 and a beta of 0.82. The company has a debt-to-equity ratio of 0.74, a quick ratio of 3.40 and a current ratio of 3.72. The business’s fifty day moving average price is $117.40 and its two-hundred day moving average price is $124.21.

Insmed (NASDAQ:INSM) last issued its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.61. Insmed had a negative return on equity of 123.94% and a negative net margin of 76.94%.The firm had revenue of $425.49 million during the quarter, compared to the consensus estimate of $395.50 million. During the same quarter in the prior year, the business posted ($1.70) earnings per share. Insmed’s revenue for the quarter was up 296.1% on a year-over-year basis. Analysts forecast that Insmed, Inc. will post -1.83 EPS for the current year.

Analyst Upgrades and Downgrades

INSM has been the subject of a number of research analyst reports. UBS Group restated a “buy” rating and issued a $172.00 price target on shares of Insmed in a research note on Friday, August 7th. Evercore reiterated an “outperform” rating and set a $170.00 price objective on shares of Insmed in a research note on Friday, August 7th. Royal Bank Of Canada decreased their price objective on shares of Insmed from $205.00 to $195.00 and set an “outperform” rating for the company in a report on Friday, June 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of Insmed in a research report on Friday, July 17th. Finally, JPMorgan Chase & Co. cut their target price on shares of Insmed from $179.00 to $175.00 and set an “overweight” rating on the stock in a research note on Monday, August 10th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $205.52.

Institutional Trading of Insmed

Institutional investors and hedge funds have recently made changes to their positions in the stock. Reflection Asset Management bought a new stake in shares of Insmed in the 4th quarter worth approximately $30,000. CIBC Private Wealth Group LLC grew its stake in Insmed by 42.1% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 53 shares during the last quarter. Raiffeisen Bank International AG bought a new position in Insmed during the 4th quarter worth $32,000. Larson Financial Group LLC increased its position in Insmed by 137.0% in the fourth quarter. Larson Financial Group LLC now owns 256 shares of the biopharmaceutical company’s stock worth $45,000 after buying an additional 148 shares during the period. Finally, Towarzystwo Funduszy Inwestycyjnych PZU SA acquired a new stake in Insmed in the fourth quarter worth $49,000.

Insmed Company Profile

Insmed Incorporated (NASDAQ: INSM) is a global biopharmaceutical company focused on developing and commercializing therapies for serious and rare diseases. The company’s work centers on areas of significant unmet medical need, including pulmonary and infectious diseases, as well as other specialty conditions.

Insmed’s primary commercial product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled antibacterial therapy approved in the United States for adults with refractory Mycobacterium avium complex lung disease as part of a combination antibacterial regimen.